01—Abstract
Summary
Summary of the 10-Q filed February 7, 2025. Cited figures are marked; the original filing is the authoritative source.
STERIS plc (STE) reported results for the third quarter and first nine months of fiscal 2025 (quarter ended December 31, 2024) in this Form 10-Q.
Total revenues rose 5.6% to $1,370.6 milliona in the quarter and 7.0% to $3,979.0 million for the nine months, with the filing attributing the growth to higher volume and pricing. Income from operations was $245.3 million for the quarter versus $226.5 million a year earlier, and net income attributable to shareholders was $173.5 million, or $1.75 diluted EPS from net income for the quarter. Gross profit percentage improved to 44.5% in the quarter from 43.2%, while restructuring expenses increased to $33.1 million for the nine months under the Restructuring Plan announced in May 2024.
Balance sheet and cash flow changes were significant. The company completed the sale of its Dental segment, which closed May 31, 2024 for total cash consideration of $787.5 millionb, and the filing states that a majority of the proceeds were used to pay off existing debt. Total debt fell to $2.16 billion from $3.21 billion at March 31, 2024, and the debt-to-total capital ratio was 25.2% at December 31, 2024, versus 33.7% at March 31, 2024.
Net cash provided by operating activities was $887.3 millionc for the nine months, and free cash flow was $588.1 million, compared with $457.0 million a year earlier. The company repurchased 907,158 shares for $200.0 million during the nine months and paid $1.66 per share in cash dividends. The filing also discloses a pending legal matter: an ethylene oxide litigation in Illinois involving approximately 250 individual plaintiffs, where a first trial ended in a mistrial on January 17, 2025 and retrial is scheduled for May 2025.
Management considers a loss reasonably possible but states that a range of loss cannot be reasonably estimated, and no amounts have been accrued. Separately, the company received two IRS Notices of Deficiency with a potential cumulative tax liability of approximately $50 milliond, which it is contesting in U.S. Tax Court, with no reserves established.
02—Key points
Key Highlights
- Total revenues increased 5.6% to $1,370.6 million for the quarter and 7.0% to $3,979.0 million for the nine months ended December 31, 2024, reflecting higher volume and pricing.
- Income from operations was $245.3 million for the quarter, up from $226.5 million, and $650.5 million for the nine months, up from $615.8 million.
- Gross profit percentage was 44.5% for the quarter versus 43.2% a year earlier, with favorable pricing and mix offset by labor and overhead costs.
- Total debt declined to $2.16 billion from $3.21 billion at March 31, 2024, after proceeds from the Dental segment sale were used largely to repay debt; the debt-to-total capital ratio was 25.2%.
- Free cash flow was $588.1 million for the nine months, compared with $457.0 million a year earlier, driven primarily by higher collections on accounts receivable and improved inventory management.
- The company repurchased 907,158 ordinary shares for $200.0 million in the first nine months and paid cash dividends of $1.66 per share.
- Ethylene oxide litigation in Illinois involves approximately 250 plaintiffs; a loss is reasonably possible but cannot be estimated, and no amounts have been accrued.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Steris kept $0.13.
- Revenue$1.37B100.0%
- Cost of revenue−$760.3M55.5%
- Gross profit$610.3M44.5%
- Operating costs−$365.0M26.6%
- Operating income$245.3M17.9%
- Interest, other & tax−$71.8M5.2%
- Net income$173.5M12.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed February 7, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $1.37B$1.30B | +5.6% |
| Cost of Revenue | $760.20M$737.70M | +3.1% |
| Gross Profit | $610.30M$560.03M | +9.0% |
| R&D Expenses | $27.40M$25.25M | +8.5% |
| SG&A Expenses | $335.50M$308.30M | +8.8% |
| Operating Expenses | $365.00M$333.56M | +9.4% |
| Operating Income | $245.30M$226.47M | +8.3% |
| Net Income | $173.50M$140.74M | +23.3% |
| EPS (Basic) | $1.76$1.42 | +23.9% |
| EPS (Diluted) | $1.75$1.42 | +23.2% |
| Shares Outstanding (Basic) | 98.50M98.80M | −0.3% |
| Shares Outstanding (Diluted) | 98.90M99.35M | −0.5% |
05—Questions
Frequently Asked Questions
How did STERIS perform in the third quarter of fiscal 2025?
Total revenues rose 5.6% to $1,370.6 million, and income from operations increased to $245.3 million from $226.5 million. Net income attributable to shareholders was $173.5 million, or $1.75 per diluted share, compared with $1.42 in the prior-year quarter. The filing attributes the revenue increase to higher volume and pricing.
What drove the change in the company's debt and balance sheet?
Total debt decreased to $2,163.7 million at December 31, 2024 from $3,206.1 million at March 31, 2024. The filing states that a majority of the Dental segment sale proceeds were used to pay off existing debt, including $638.1 million of term loan repayments and $80.0 million of Private Placement Senior Notes repaid during the nine months.
What is the status of the Dental segment divestiture?
The Dental segment was sold for total cash consideration of $787.5 million, subject to customary adjustments, plus up to an additional $12.5 million contingent on certain fiscal 2025 revenue targets. The transaction was structured as an equity sale and closed on May 31, 2024, and Dental is reported as discontinued operations.
What legal and tax risks does the filing disclose?
The company faces ethylene oxide litigation in Illinois with about 250 plaintiffs; the first trial ended in a mistrial on January 17, 2025, with retrial scheduled for May 2025, and no amounts have been accrued. Separately, two IRS Notices of Deficiency relate to a potential cumulative tax liability of approximately $50 million, which the company is contesting in U.S. Tax Court without establishing reserves.
What is the restructuring plan and its expected impact?
In May 2024 the company adopted a Restructuring Plan that includes a strategic shift in its European Healthcare surgical business, along with other actions, and eliminates fewer than 300 positions. Restructuring expenses were $33.1 million for the nine months, with total expense of $77.5 million recorded since inception, and the company expects approximately $20.0 million of additional costs, primarily through the remainder of fiscal 2025.
06—Continue